Prevention of vertical transmission of HIV-1 in resource-limited settings

References

• Bertolli J, St Louis ME, Simonds RJ et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J. Infect. Dis.174, 722–726 (1996).
   PubMed Web of Science ®Google Scholar
• Mock PA, Shaffer N, Bhadrakom C et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS13, 407–414 (1999).
   PubMed Web of Science ®Google Scholar
• Charurat M, Datong P, Matawal B, Ajene A, Blattner W, Abimiku A. Timing and determinants of mother-to-child transmission of HIV in Nigeria. Int. J. Gynecol. Obstet.106(1), 8–13 (2009).
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamividine–zidovudine combination for prevention of maternal–infant transmission of HIV. JAMA285(16), 2083–2093 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr.29(5), 484–494 (2002).
   PubMed Web of Science ®Google Scholar
• Dorenbaum A, Cunningham CK, Gelber RD et al. Two-dose intra-partum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA288(2), 189–198 (2002).
   PubMed Web of Science ®Google Scholar
• Haberl A, Linde R, Reitter A et al. Safety and efficacy of tenofovir in pregnant women. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 627a).
   Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS22, 973–981 (2008).
   PubMed Web of Science ®Google Scholar
• von Linstow ML, Rosenfeldt V, Lebech AM et al. Prevention of mother-to-child transmission of HIV in Denmark, 1994–2008. HIV Med.11(7), 448–456 (2010).
   PubMedGoogle Scholar
• Islam S, Oon V, Thomas P. Outcome of pregnancy in HIV-positive women planned for vaginal delivery under effective antiretroviral therapy. J. Obstet. Gynaecol.30(1), 38–40 (2010).
   PubMedGoogle Scholar
• Gumbo FZ, Duri K, Kandawasvika GQ et al. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting. J. Perinatol. DOI: 10.1038/jp.2010.31 (2010) (Epub ahead of print).
   Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N. Engl. J. Med.340, 977–987 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou Z, Meyers K, Li X et al. Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China. J. Acquir. Immune Defic. Syndr.53(Suppl. 1), S15–S22 (2010).
   Google Scholar
• Connor EM, Sperling RS, Gelber R et al.; The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med.331(18), 1173–1180 (1994).
   PubMed Web of Science ®Google Scholar
• Dabis F, Msellati P, Meda N et al. 6-Month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet353(9155), 786–792 (1999).
   PubMed Web of Science ®Google Scholar
• Wiktor SZ, Ekpini E, Karon JM et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet353(9155), 781–785 (1999).
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, Le Coeur S et al. A trial of short zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N. Engl. J. Med.343, 982–991 (2000).
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet354(9181), 795–802 (1999).
   PubMed Web of Science ®Google Scholar
• Moodley D, Moodley J, Coovadia H et al. A multicentre randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis.187, 725–735 (2003).
   PubMed Web of Science ®Google Scholar
• The PETRA Study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (PETRA Study): a randomised, double-blind placebo-controlled trial. Lancet359, 1178–1186 (2002).
   PubMed Web of Science ®Google Scholar
• McIntyre JA, Martinson N, Gray GE et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment and Prevention. Rio de Janiero, Brazil, 24–27 July 2005.
   Google Scholar
• Arrivé E, Chaix ML, Nerrienet E et al. The TEmAA ANRS 12109 Phase II trial, Step 1: tolerance and viral resistance after single-dose nevirapine and short-course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 45B).
   Google Scholar
• Chi BH, Ellis GM, Chintu N et al. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Res. Hum. Retroviruses25(11), 1099–1106 (2009).
   PubMedGoogle Scholar
• Fawzi W, Msamanga G, Spielgelman D et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet351(9114), 1477–1482 (1998).
   PubMed Web of Science ®Google Scholar
• Kawai K, Kupka R, Mugusi F et al. A randomized trial to determine the optimal dosage of multivitamin supplements to reduce adverse pregnancy outcomes among HIV-infected women in Tanzania. Am. J. Clin. Nutr.91(2), 391–397 (2010).
   PubMed Web of Science ®Google Scholar
• Fawzi WW, Msamanga G, Hunter D et al. Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J. Acquir. Immune Defic. Syndr.23(3), 246–254 (2000).
   PubMed Web of Science ®Google Scholar
• Kongnyuy EJ, Wiysonge CS, Shey MS. A systematic review of randomized controlled trials of prenatal and postnatal vitamin A supplementation of HIV-infected women. Int. J. Gynaecol. Obstet.104(1), 5–8 (2009).
   PubMedGoogle Scholar
• Kawai K, Msamanga G, Manji K et al. Sex differences in the effects of maternal vitamin supplements on mortality and morbidity among children born to HIV-infected women in Tanzania. Br. J. Nutr.103(12), 1784–1791 (2010).
   PubMedGoogle Scholar
• Mehta S, Giovannucci E, Mugusi FM et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One5(1), e8770 (2010).
   PubMed Web of Science ®Google Scholar
• Mehta S, Hunter DJ, Mugusi FM et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J. Infect. Dis.200(7), 1022–1030 (2009).
   PubMed Web of Science ®Google Scholar
• Villamor E, Aboud S, Koulinska IN et al. Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission. Eur. J. Clin. Nutr.60(7), 862–869 (2006).
   PubMed Web of Science ®Google Scholar
• Fawzi W, Villamor E, Msamanga GI et al. Trial of zinc supplements in relation to pregnancy outcomes, hematologic indicators, and T cell counts among HIV-1-infected women in Tanzania. Am. J. Clin. Nutr.81(1), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Kupka R, Garland M, Msamanga G, Spiegelman D, Hunter D, Fawzi W. Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr.39(2), 203–210 (2005).
   PubMed Web of Science ®Google Scholar
• Kupka R, Mugusi F, Aboud S et al. Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes. Am. J. Clin. Nutr.87(6), 1802–1808 (2008).
   PubMed Web of Science ®Google Scholar
• Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst. Rev.4, CD005479 (2005).
   PubMedGoogle Scholar
• Boer K, England K, Godfried MH, Thorne C; the European Collaborative Study. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med.11(6), 368–378 (2010).
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Goedert JJ, Miotti PG et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet347, 1647–1650 (1996).
   PubMed Web of Science ®Google Scholar
• Msellati P, Meda N, Leroy V et al. Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b Phase II randomized, double blinded placebo controlled trial. DITRAME Study Group. Sex. Transm. Infect.75, 420–425 (1999).
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Msellati P, Meda N et al. 15 month follow up of African children following vaginal cleansing with benzalkonium chloride of their HIV infected mothers during late pregnancy and delivery. Sex. Transm. Infect.78, 267–270 (2002).
   PubMed Web of Science ®Google Scholar
• Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet362, 65–71 (2003).
   PubMed Web of Science ®Google Scholar
• Arifeen S, Black RE, Antelman G, Baqui A, Caulfield L, Becker S. Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. Pediatrics108, E67 (2001).
   PubMed Web of Science ®Google Scholar
• Bhandari N, Bahl R, Mazumdar S et al. Effect of community-based promotion of exclusive breastfeeding on diarrhoeal illness and growth: a cluster randomised controlled trial. Lancet361, 1418–1423 (2003).
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Cambridge, MA, USA. Global Burden of Disease and Injury Series, Volume I (1996).
   Google Scholar
• Short RV, Lewis PR, Renfree MB, Shaw G. Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus. Lancet337, 715–717 (1991).
   PubMed Web of Science ®Google Scholar
• Stein Z, Kuhn L. Breast feeding: a time to craft new policies. J. Public Health Policy30, 300–310 (2009).
   PubMedGoogle Scholar
• Nelson AM. A metasynthesis of qualitative breastfeeding studies. J. Midwifery Womens Health51(2), e13–e20 (2006).
   PubMedGoogle Scholar
• Creek T. Role of infant feeding and HIV in a severe outbreak of diarrhoea and malnutrition among young children – Botswana, 2006. Presented at: President’s Emergency Plan for AIDS Relief Emergency Meeting/2006 HIV/AIDS Implementers’ Meeting. Durban, South Africa, 12–15 June 2006.
   Google Scholar
• Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr. Opin. Pediatr.21, 83–93 (2009).
   PubMed Web of Science ®Google Scholar
• Lehman DA, Chung MH, Mabuka JM et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J. Acquir. Immune Defic. Syndr.51(5), 522–529 (2009).
   PubMed Web of Science ®Google Scholar
• Palombi L, Marazzi MC, Voetberg A, Magid NA; the DREAM Program Prevention of Mother-to-Child Transmission team. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS21(Suppl. 4), S65–S71 (2007).
   Web of Science ®Google Scholar
• Leroy V, Ekouevi DK, Becquet R et al. 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. PLoS One3(2), e1645 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Black V, Technau K et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J. Acquir. Immune Defic. Syndr.54(1), 35–41 (2010).
   PubMed Web of Science ®Google Scholar
• Shapiro R, Hughes M, Ogwu A et al. A randomized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child transmission among breast-feeding women in Botswana (The Mma Bana Study). Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19–22 July 2009 (Abstract WeLBB101).
   Google Scholar
• Ekouevi DK, Coffie PA, Becquet R et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d’Ivoire. AIDS22, 1815–1820 (2008).
   PubMed Web of Science ®Google Scholar
• Tonwe-Gold B, Ekouevi DK, Viho I et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med.4(8), e257 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas T, Masaba R, Ndivo R et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003–2007. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 45aLB).
   Google Scholar
• Kilewo C, Karlsson K, Ngarina M et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J. Acquir. Immune Defic. Syndr.52(3), 406–416 (2009).
   PubMed Web of Science ®Google Scholar
• Peltier CA, Ndayisaba GF, Lepage P et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS23(18), 2415–2423 (2009).
   PubMed Web of Science ®Google Scholar
• De Vincenzi I (for Kesho Bora Study Group). Triple-antiretroviral prophylaxis during pregnancy and breast-feeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya and South Africa. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19–22 July 2009 (Abstract LBPeC01).
   Google Scholar
• Marazzi MC, Nielsen-Saines K, Buonomo E et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr. Infect. Dis. J.28, 483–487 (2009).
   PubMedGoogle Scholar
• Thior I, Lockman S, Smeaton LM et al. Breast-feeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA296, 794–805 (2006).
   PubMed Web of Science ®Google Scholar
• Bedri A, Gudetta B, Isehak A et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breast-feeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet372, 300–313 (2008).
   PubMed Web of Science ®Google Scholar
• Kumwenda NI, Hoover DR, Mofenson LM et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med.359, 119–129 (2008).
   PubMed Web of Science ®Google Scholar
• Kilewo C, Karlsson K, Massawe A et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J. Acquir. Immune Defic. Syndr.48, 315–323 (2008).
   PubMed Web of Science ®Google Scholar
• Chasela C, Hudgens M, Jamieson D et al. Both maternal HAART and daily infant nevirapine are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breast-feeding, Antiretroviral and Nutrition (BAN) Study. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, 19–22 July 2009 (Abstract WeLBC103).
   Google Scholar
• Taha TE, Kumwenda J, Cole SR et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J. Infect. Dis.200(10), 1490–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Church JD, Omer SB, Guay LA et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J. Infect. Dis.198, 1075–1082 (2008).
   PubMedGoogle Scholar
• Eshleman SH, Guay LA, Mwatha A et al. Characterization of nevirapine resistance mutations in women with subtype A vs D HIV-1 6–8 weeks after single-dose nevirapine (HIVNET 012). J. Acquir. Immune Defic. Syndr.35, 126–130 (2004).
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med.355, 2283–2296 (2006).
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and those not receiving ART at baseline in the SMART study. J. Infect. Dis.197, 1133–1144 (2008).
   PubMed Web of Science ®Google Scholar
• Danel C, Moh R, Minga A et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet367, 1981–1989 (2006).
   PubMed Web of Science ®Google Scholar
• Chaix M, Ekouevi DK, Rouet F et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d’Ivoire. J. Infect. Dis.193, 482–487 (2006).
   PubMedGoogle Scholar
• Coffie PA, Ekouevi DK, Chaix M et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003–2006. Clin. Inf. Dis.46(4), 611–621 (2008).
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Chaix ML, Blanche S et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology6, 85 (2009).
   PubMed Web of Science ®Google Scholar
• Torres Rivera B, Vallés V, Ríos Olivares E. Prevalence of primary and secondary resistant mutations to antiretroviral drug in a population of Puerto Rican infected with HIV. P. R. Health Sci. J.21(4), 329–336 (2002).
   PubMedGoogle Scholar
• Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis.192, 24–29 (2005).
   PubMedGoogle Scholar
• Delaugerre C, Rohban R, Simon A et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol.65(3), 445–448 (2001).
   PubMed Web of Science ®Google Scholar
• Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T et al. Antiretroviral resistance patterns and HIV-1 subtype in mother–infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin. Infect. Dis.49(2), 299–305 (2009).
   PubMedGoogle Scholar
• Jourdain G, Wagner TA, Ngo-Giang-Huong N et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin. Infect. Dis.50(10), 1397–1404 (2010).
   PubMedGoogle Scholar
• Arrivé E, Newell ML, Ekouevi DK et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol.36(5), 1009–1021 (2007).
   PubMed Web of Science ®Google Scholar
• Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med.351(3), 229–240 (2004).
   PubMed Web of Science ®Google Scholar
• Chi BH, Sinkala M, Stringer EM et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS21, 957–964 (2007).
   PubMed Web of Science ®Google Scholar
• Lockman S, Shapiro RL, Smeaton LM et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med.356, 135–147 (2007).
   PubMed Web of Science ®Google Scholar
• Palumbo P, Violari A, Lindsey J et al. Nevirapine (NVP) vs lopinavir–ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July 2009 (Abstract LBPEB12).
   Google Scholar
• Martinson NA, Ekouevi DK, Dabis F et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa, and Abidjan, Cote d’Ivoire. J. Acquir. Immune Defic. Syndr.45, 206–209 (2007).
   PubMedGoogle Scholar
• Eshleman SH, Mracna M, Guay LA et al. Selecting and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS15, 1951–1957 (2001).
   PubMed Web of Science ®Google Scholar
• Stringer JS, McConnell MS, Kiarie J et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med.7(2), e1000233 (2010).
   PubMed Web of Science ®Google Scholar
• Micek MA, Blanco AJ, Beck IA et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin. Infect. Dis.50(10), 1405–1414 (2010).
   PubMedGoogle Scholar
• McIntyre JA, Hopley M, Moodley D et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Clin. Trials6(10), 1–9 (2009).
   Google Scholar
• Jamisse L, Balkus J, Hitti J et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J. Acquir. Immune Defic. Syndr.44, 371–376 (2007).
   PubMed Web of Science ®Google Scholar
• Gingelmaier A, Eberle J, Kost BP et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin. Infect. Dis.50(6), 890–894 (2010).
   PubMedGoogle Scholar
• Ginglemaier A, Kurowski M, Kastner R et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS20, 1737–1743 (2006).
   PubMedGoogle Scholar
• Burchette S, Best B, Mirochnick M et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007 (Abstract 738b).
   Google Scholar
• Ivanovic J, Nicastri E, Anceschi MM et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr. HIV Res.7(6), 620–625 (2009).
   PubMed Web of Science ®Google Scholar
• Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin. Trials10(1), 41–47 (2009).
   PubMed Web of Science ®Google Scholar
• McKoy JM, Bennett CL, Scheetz MH et al. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use. Drug Safety32(2), 147–158 (2009).
   PubMed Web of Science ®Google Scholar
• Le Chenadec J, Mayaux M, Guihenneuc-Jouyaux C, Blanche S; Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants. AIDS17, 2053–2061 (2003).
   PubMed Web of Science ®Google Scholar
• Lahoz R, Noguera A, Rovira N et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr. Infect. Dis. J.29(4), 376–379 (2010).
   PubMed Web of Science ®Google Scholar
• Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N. Engl. J. Med.346, 1863–1870 (2002).
   PubMed Web of Science ®Google Scholar
• Thorne C, Patel D, Newell M. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS18, 2337–2339 (2004).
   PubMed Web of Science ®Google Scholar
• Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-1 infected women in the United Kingdom and Ireland. AIDS21, 1019–1026 (2007).
   PubMed Web of Science ®Google Scholar
• Briand N, Mandelbrot L, Le Chenadec J et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS23(10), 1235–1243 (2009).
   PubMed Web of Science ®Google Scholar
• Briand N, Lallemant M, Jourdain G et al. Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial. PLoS Clin. Trial2(4), e11 (2007).
   Google Scholar
• Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics125(2), e250–e260 (2010).
   PubMed Web of Science ®Google Scholar
• Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med.10(7), 397–406 (2009).
   PubMed Web of Science ®Google Scholar
• The Kesho Bora Study Group. HIV free survival at 12 months among children born to HIV-infected women receiving antiretrovirals (ARVs) from 18–36 weeks of pregnancy. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 638).
   Google Scholar
• Baek C, Rutenberg N. Implementing programs for the prevention of mother-to-child HIV transmission in resource-constrained settings: horizons studies, 1999–2007. Public Health Reports125(2), 293–304 (2010).
   PubMed Web of Science ®Google Scholar
• Nyandiko WM, Otieno-Nyunya B, Musick B et al. Outcomes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child transmission in a resource-constrained setting. J. Acquir. Immune Defic. Syndr.54(1), 42–50 (2010).
   PubMedGoogle Scholar
• Chen JY, Ogwu AC, Svab P et al. Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4+ cell counts in Gaborone, Botswana. J. Acquir. Immune Defic. Syndr.54(1), 102–106 (2010).
   PubMed Web of Science ®Google Scholar
• Peltzer K, Mlambo G. Factors determining HIV viral testing of infants in the context of mother-to-child transmission. Acta Paediatr.99(4), 590–596 (2010).
   PubMed Web of Science ®Google Scholar
• Kasenga F, Byass P, Emmelin M, Hurtig AK. The implications of policy changes on the uptake of a PMTCT programme in rural Malawi: first three years of experience. Glob. Health Action DOI: 10.3402/gha.v2i0.1883 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Mandala J, Torpey K, Kasonde P et al. Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Public Health9, 314 (2009).
   PubMed Web of Science ®Google Scholar
• Torpey K, Kabaso M, Kasonde P et al. Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv. Res.10, 29 (2010).
   PubMed Web of Science ®Google Scholar
• Petruney T, Robinson E, Reynolds H, Wilcher R, Cates W. Contraception is the best kept secret for prevention of mother-to-child HIV transmission. Bull. World Health Organ.86(6), B (2008).
   PubMedGoogle Scholar
• Peltzer K, Chao L-W, Dana P. Family planning among HIV positive and negative prevention of mother to child transmission (PMTCT) clients in a resource poor setting in South Africa. AIDS Behav.13(5), 973–979 (2009).
   PubMed Web of Science ®Google Scholar
• Nuesch R, Ananworanich J, Srasuebkul P et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS22(1), 152–154 (2008).
   PubMedGoogle Scholar